China has four COVID 19 vaccines in the final stages of clinical trials. At least three of these have already been offered to employees in priority areas as part of an emergency program launched in July.
The third phase of the clinical trials is running smoothly, and the vaccines could be ready for the general public in November or December, CDC chief Guizhen Wu, a biosecurity expert, said in an interview with Chinese state television.
Guizhen Wu, who said he had not experienced any abnormal symptoms in recent months after being given an experimental vaccine in April, did not mention which vaccines he was referring to.
A unit of the pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and Sinovac Biotech, listed in China, is developing the three vaccines as part of a state emergency use program. A fourth COVID 19 vaccine, developed by CanSino Biologics, was approved for use by the Chinese military in June.
Sinopharm said in July that its vaccine could be ready for the general public by the end of this year after the completion of the third phase of clinical trials.